retatrutide efficacy clinical trials and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Clinical trials of subcutaneous tirzepatide,

In a longitudinal study of such patients, mean pro-C3 increased with worsening of fibrosis and decreased with fibrosis improvement 36

At that point, the amount of drug leaving your body is balanced by the amount youre adding with each new dose, creating a reliable therapeutic effect

All included supplies are selected to support structured research workflows, with secure packaging to maintain integrity during transit across Australia

For a detailed head-to-head comparison, see our retatrutide vs tirzepatide comparison guide

These symptoms can overlap with and potentially worsen the gastrointestinal effects already associated with GLP-1 therapy, making it difficult to distinguish which agent is responsible for adverse effects

No compounded option